Stock Events

Stock Events

Immunovia AB 

€0.021000
0
+€0.00+0% Thursday 07:12

Statistics

Day High
0.021
Day Low
0.021
52W High
0.05933
52W Low
0.0123
Volume
-
Avg. Volume
-
Mkt Cap
14.13M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q4 0
Q1 2026
Next
-0
-0
-0
-0
Expected EPS
-0.00359647184
Actual EPS
N/A

Financials

-21,174.18%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
62,818.18Revenue
-13.3MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1YR.MU. It's not an investment recommendation.
NVIDIA
2
NVDA
Coinbase Global
2
COIN
SAAB AB
2
SAAB-B.ST

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap21.22B
Guardant Health provides liquid biopsy tests for cancer diagnostics, overlapping with Immunovia's focus on early cancer detection using blood-based biomarkers.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG develops diagnostic tools and technologies for detecting various diseases including cancer, similar to Immunovia's diagnostic solutions.
Illumina
ILMN
Mkt Cap28.78B
Illumina, Inc. offers genomic sequencing solutions used in cancer and other health diagnostics, competing in the broader market of molecular diagnostics.
Qiagen NV
QGEN
Mkt Cap8.56B
Qiagen N.V. provides sample and assay technologies for molecular diagnostics, competing with Immunovia in the field of precision medicine and diagnostics.
Quest Diagnostics
DGX
Mkt Cap22.96B
Quest Diagnostics incorporates advanced diagnostics for conditions including cancer, directly competing with Immunovia's diagnostic tests.
Bio-Rad Laboratories
BIO
Mkt Cap7.92B
Bio-Rad Laboratories, Inc. specializes in clinical diagnostics and life science research, offering products that compete in the diagnostics market.
Fulgent Genetics
FLGT
Mkt Cap583.63M
Fulgent Genetics, Inc. focuses on genetic testing to detect cancer and other diseases, competing with Immunovia's genomic and proteomic testing approaches.
Myriad Genetics
MYGN
Mkt Cap550.63M
Myriad Genetics, Inc. provides molecular diagnostic tests that assess the risk of developing cancer, competing with Immunovia's focus on early detection and risk assessment.

About

Immunovia AB engages in the development of methods for diagnosing complex forms of cancer and autoimmune diseases. Its technology platform, IMMray, focuses on the early diagnosis of cancer, predicts disease progression, and monitors therapeutic responsiveness of cancers. The company was founded by Karl Arne Krister Borrebaeck on May 24, 2007 and is headquartered in Lund, Sweden.
Show more...
CEO
ISIN
SE0006091997

Listings

MU
DE
1YR.MU
LSE
GB
0G8X.LSE
ST
SE
IMMNOV.ST
F
DE
1YR.F

0 Comments

Share your thoughts

FAQ

What is Immunovia AB stock price today?▼
The current price of 1YR.MU is €0.02 EUR — it has increased by +0% in the past 24 hours. Watch Immunovia AB stock price performance more closely on the chart.
What is Immunovia AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Immunovia AB stocks are traded under the ticker 1YR.MU.
Is Immunovia AB stock price growing?▼
1YR.MU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Immunovia AB has showed a -28.74% decrease.
What is Immunovia AB market cap?▼
Today Immunovia AB has the market capitalization of 14.13M
When is the next Immunovia AB earnings date?▼
Immunovia AB is going to release the next earnings report on August 06, 2026.
What were Immunovia AB earnings last quarter?▼
1YR.MU earnings for the last quarter are -0 EUR per share, whereas the estimation was -0 EUR resulting in a +3.54% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Immunovia AB revenue for the last year?▼
Immunovia AB revenue for the last year amounts to 62,818.18 EUR.
What is Immunovia AB net income for the last year?▼
1YR.MU net income for the last year is -13.3M EUR.
In which sector is Immunovia AB located?▼
Immunovia AB operates in the Other sector.
When did Immunovia AB complete a stock split?▼
The last stock split for Immunovia AB was on February 03, 2026 with a ratio of 1:100.